Phibro Animal Health Corporation — Form 10-Q Summary
Reporting period: Quarterly and nine-month periods ended March 31, 2024, compared with the corresponding periods ended March 31, 2023. Although the request identifies “2023 Q3,” the filing is for fiscal 2024 third quarter. The financial statements are unaudited.
Business context
Phibro develops, manufactures and markets animal health, mineral nutrition and performance products for food and companion animals. Its segments are Animal Health, Mineral Nutrition and Performance Products. The company operates globally, including substantial manufacturing and operating activities in Israel.
Financial performance and liquidity
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 | Nine months ended March 31, 2024 | Nine months ended March 31, 2023 |
|---|---|---|---|---|
| Net sales | $263.2 million | $245.7 million | $744.5 million | $722.8 million |
| Gross profit | $79.6 million | $75.5 million | $225.9 million | $221.6 million |
| Gross margin | 30.2% | 30.7% | 30.3% | 30.7% |
| Operating income | $19.9 million | $18.6 million | $34.9 million | $48.1 million |
| Net income | $8.4 million | $10.0 million | $1.7 million | $21.1 million |
| Diluted EPS | $0.21 | $0.25 | $0.04 | $0.52 |
| Adjusted EBITDA | $29.7 million | $27.4 million | $77.8 million | $80.4 million |
| Adjusted net income | $12.7 million | $11.6 million | $31.7 million | $33.8 million |
Quarterly net sales increased 7%, while nine-month sales increased 3%. Quarterly operating income rose 7%, but nine-month operating income declined 27%. Quarterly net income decreased 16%; nine-month net income decreased $19.4 million. The filing attributes the nine-month decline primarily to higher SG&A, foreign-currency losses and interest expense.
- Segment sales: Nine-month Animal Health sales increased 7% to $515.0 million, led by MFAs and vaccines. Mineral Nutrition declined 1% to $181.6 million, and Performance Products declined 14% to $47.9 million.
- Segment profitability: Nine-month Animal Health Adjusted EBITDA increased 6% to $104.3 million. Mineral Nutrition Adjusted EBITDA declined 18% to $11.1 million, and Performance Products declined 35% to $4.6 million.
- Cost pressures: Nine-month SG&A increased 10% to $191.0 million. Included were a $10.7 million pension settlement cost, $4.2 million of Brazil employment taxes, $0.5 million of acquisition-related costs and $0.3 million of stock-based compensation.
- Foreign currency: Net foreign-currency losses increased to $16.6 million for the nine-month period from $4.6 million, primarily reflecting currency fluctuations and a major devaluation in Argentina.
- Interest expense: Net interest expense increased 27% for the nine-month period to $13.8 million, reflecting higher variable rates and increased debt levels.
- Cash flow: Nine-month operating cash flow was $59.2 million versus a use of $6.9 million in the prior-year period. Investing cash flow was negative $39.1 million, including $28.2 million of capital expenditures, $8.5 million of net short-term investment purchases and $3.3 million for an acquisition. Financing cash flow was negative $8.6 million, including $14.6 million of dividends.
- Balance sheet: At March 31, 2024, cash and cash equivalents were $50.2 million and short-term investments were $48.5 million. Total debt, including current and long-term portions and the revolver, was approximately $485.8 million before considering cash and investments.
- Liquidity: Working capital was $339.2 million and the current-assets-to-current-liabilities ratio was 3.13:1. Revolver borrowings were $165.0 million, with $142.7 million available, subject to facility restrictions. Management expects adequate liquidity for at least the next 12 months, but notes that the planned acquisition will materially increase funding needs.
Material changes versus the prior comparable period
- Sales growth was concentrated in Animal Health, while Performance Products weakened materially and Mineral Nutrition was broadly flat to down.
- Gross margin declined 50 basis points in the quarter and 40 basis points year to date because of unfavorable product mix.
- Quarterly Adjusted EBITDA increased 9%, but nine-month Adjusted EBITDA declined 3% because of weaker Mineral Nutrition and Performance Products results and higher corporate costs.
- The nine-month results include unusual items not present, or not comparable, in the prior period, particularly the pension settlement and Brazil employment-tax charge. The prior-year period included $6.9 million of environmental remediation costs.
- Cash generation improved substantially, aided by working-capital changes, including favorable accounts payable and accrued-liability timing.
Guidance, outlook, risks and unusual items
- Zoetis acquisition: In April 2024, Phibro agreed to acquire Zoetis’s MFA product portfolio, certain water-soluble products and related assets for $350.0 million, subject to adjustments and customary closing conditions. Phibro expects to fund the transaction with approximately $325.0 million of new debt and, if necessary, cash. A debt commitment letter has been obtained, but funding remains subject to customary conditions.
- Carbadox/Mecadox regulatory matter: The FDA revoked the approved method for detecting carbadox residues and proposed withdrawing approvals for carbadox products. Phibro requested a full evidentiary hearing and filed a lawsuit challenging the revocation order. Mecadox sales were approximately $20.0 million for the 12 months ended March 31, 2024. Loss of approval could adversely affect results.
- Israel conflict: Phibro has approximately 500 employees and three manufacturing sites in Israel. Israeli operations represented 28% of consolidated assets at March 31, 2024, and 21% of nine-month net sales. The company reported no material disruption from the April 2024 Iran attack, but prolonged or escalating conflict could disrupt facilities, personnel, logistics, raw materials and customers.
- Russia and Ukraine: Sales to Russia and Ukraine represented approximately 1% of consolidated net sales for the 12 months ended March 31, 2024. Additional sanctions, currency volatility, supply-chain disruption and cybersecurity risks remain possible.
- Environmental contingencies: Estimated environmental investigation, remediation and closure liabilities were approximately $4.3 million at March 31, 2024. The Omega Chemical Site settlement payments had been made, but formal regulatory and court approval remained pending.
- Debt and interest-rate exposure: Credit facilities mature in April 2026 and require compliance with leverage and interest-coverage covenants. Phibro was in compliance at March 31, 2024. A $300.0 million interest-rate swap fixes the floating SOFR component through June 2025, but the planned acquisition is expected to increase leverage and debt-service obligations.
- Dividends: The company declared a $0.12-per-share dividend payable June 26, 2024, subject to the Board’s approval process and debt-agreement limitations.
- Outlook: The filing provides no specific numerical revenue, earnings or Adjusted EBITDA guidance. Management expects ongoing liquidity for at least 12 months but cautions that acquisition funding, adverse operating results, covenant violations and market conditions could affect future liquidity.
Most important facts for investors to verify
- Closing conditions, final financing terms and pro forma leverage associated with the $350.0 million Zoetis MFA acquisition.
- Progress and outcome of the FDA carbadox proceedings and the potential impact on approximately $20.0 million of annual sales.
- Whether Animal Health growth can offset continued weakness in Mineral Nutrition and Performance Products.
- Foreign-currency exposure, particularly the effects of Argentine currency devaluation, and the sustainability of recent cash-flow improvement.
- Compliance with debt covenants and the April 2026 maturity of the principal credit facilities after the planned borrowing.
- Operational continuity and supply-chain exposure related to the company’s Israeli manufacturing footprint.
- The extent to which pension, Brazil employment-tax, acquisition and other unusual items affect comparability of GAAP and non-GAAP results.